Alzheimer's Disease and Tau and several other neurodegenerative diseases, page-17

I just love it when a bit of research seems to be coming together!
I believe this particular part is very important-:
"Andrew Heaton PhD, Novogen Group Vice-President of Drug Discovery and Manufacture, said, “The application of our VAL-ID (Versatile Approach to Library based Iterative Design) strategy has now been successfully executed on the ATM technology platform. This process has allowed us to extend the chemistry around our original ATM hit compounds, generating an entirely new family of compounds designed to target the tropomyosin protein"

Because what this means is that the manufacturing method they used, to take the original benzoporan technology to superbenzoporans, making them 1000 times more potent in the process, may also work on the ATM platform and if that is the case? then this process will work with other drugs as well you would have to assume?
If so? then that in itself is worth one hell of a lot of money to Novogen!